Ocular Therapeutix (OCUL) Common Equity (2013 - 2026)

Ocular Therapeutix's Common Equity history runs 14 years deep, the most recent figure standing at $581.6 million for Q1 2026.

• On a quarterly basis, Common Equity rose 118.69% year-over-year to $581.6 million in Q1 2026; TTM through Mar 2026 was $581.6 million, a 118.69% increase from a year earlier, with the FY2025 full-year figure at $654.3 million, up 107.49% from the prior year.
• Common Equity eased to $581.6 million in Q1 2026 per OCUL's latest filing, from $654.3 million in the prior quarter.
• Across five years, Common Equity topped out at $654.3 million in Q4 2025 and bottomed at $3.1 million in Q2 2023.
• The 5-year median for Common Equity is $258.2 million (2025), against an average of $226.9 million.
• Across the five-year window, Common Equity plunged 95.31% in 2023 and jumped 12135.02% in 2024, its largest moves.
• Year by year, Common Equity stood at $35.4 million in 2022, then surged by 157.59% to $91.1 million in 2023, then soared by 246.03% to $315.3 million in 2024, then surged by 107.49% to $654.3 million in 2025, then fell by 11.12% to $581.6 million in 2026.
• Per Business Quant, the three latest OCUL Common Equity figures stand at $581.6 million (Q1 2026), $654.3 million (Q4 2025), and $258.2 million (Q3 2025).